1832 Asset Management LP cut its holdings in shares of Becton, Dickinson and Company (NYSE: BDX – Get Rating) by 95.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 55,932 shares of the medical instruments supplier’s stock after selling 1,117,272 shares during the period. 1832 Asset Management LP’s holdings in Becton, Dickinson and were worth $ 14,317,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. Morgan Stanley grew its position in Becton, Dickinson and by 16.9% during the 2nd quarter. Morgan Stanley now owns 9,175,000 shares of the medical instruments supplier’s stock worth $ 2,231,268,000 after purchasing an additional 1,323,224 shares during the last quarter. Guggenheim Capital LLC grew its holdings in shares of Becton, Dickinson and by 14.4% during the third quarter. Guggenheim Capital LLC now owns 38,646 shares of the medical instruments supplier’s stock worth $ 9,501,000 after buying an additional 4,858 shares during the last quarter. Eaton Vance Management increased its position in Becton, Dickinson and by 5.8% in the 3rd quarter. Eaton Vance Management now owns 214,755 shares of the medical instruments supplier’s stock valued at $ 51,288,000 after acquiring an additional 11,783 shares during the period. Alberta Investment Management Corp raised its stake in Becton, Dickinson and by 0.8% during the 3rd quarter. Alberta Investment Management Corp now owns 12,500 shares of the medical instruments supplier’s stock valued at $ 3,073,000 after acquiring an additional 100 shares during the last quarter. Finally, Ancora Advisors LLC lifted its position in Becton, Dickinson and by 27.1% during the 3rd quarter. Ancora Advisors LLC now owns 9,271 shares of the medical instruments supplier’s stock worth $ 2,279,000 after acquiring an additional 1,974 shares during the period. 86.58% of the stock is currently owned by institutional investors and hedge funds.
Shares of BDX opened at $ 241.85 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.72. Becton, Dickinson and Company has a 52-week low of $ 235.13 and a 52-week high of $ 280.62. The company has a 50-day simple moving average of $ 256.98 and a 200-day simple moving average of $ 258.71. The company has a market capitalization of $ 68.94 billion, a PE ratio of 38.15, a P / E / G ratio of 3.37 and a beta of 0.64.
Becton, Dickinson and (NYSE: BDX – Get Rating) last issued its earnings results on Thursday, May 5th. The medical instruments supplier reported $ 3.18 earnings per share for the quarter, topping the consensus estimate of $ 2.98 by $ 0.20. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The company had revenue of $ 5.01 billion for the quarter, compared to analyst estimates of $ 4.78 billion. During the same period in the prior year, the business posted $ 3.19 earnings per share. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 11.2 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be paid a $ 0.87 dividend. This represents a $ 3.48 annualized dividend and a yield of 1.44%. The ex-dividend date of this dividend is Wednesday, June 8th. Becton, Dickinson and his payout ratio is currently 54.89%.
Several equities research analysts have recently commented on the company. StockNews.com upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Thursday, June 2nd. Piper Sandler cut their price objective on shares of Becton, Dickinson and from $ 265.00 to $ 255.00 in a research report on Thursday, May 5th. Bank of America began coverage on shares of Becton, Dickinson and in a report on Tuesday, March 1st. They issued a “neutral” rating on the stock. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and from $ 275.00 to $ 285.00 and gave the stock an “equal weight” rating in a report on Friday, April 1st. Finally, Argus lifted their price objective on Becton, Dickinson and from $ 275.00 to $ 310.00 in a report on Monday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $ 280.83.
In related news, VP Thomas J. Spoerel sold 443 shares of the company stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $ 260.00, for a total value of $ 115,180.00. Following the sale, the vice president now owns 1,058 shares of the company stock, valued at approximately $ 275,080. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Hickey sold 475 shares of the stock in a transaction on Friday, May 6th. The shares were sold at an average price of $ 256.00, for a total value of $ 121,600.00. Following the sale, the executive vice president now owns 3,806 shares in the company, valued at approximately $ 974,336. The disclosure for this sale can be found here. Insiders own 0.50% of the company stock.
About Becton, Dickinson and: (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE: BDX – Get Rating).
Receive News & Ratings for Becton Dickinson and Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and and related companies with MarketBeat.com’s FREE daily email newsletter.